Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06822049 · ClinicalTrials.gov registry record · Phase 2

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)

A Phase 2 study of Remote vs. In-Person and Remote Visits, sponsored by State University of New York at Buffalo.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
2
Study locations

NCT06822049 is a Phase 2 study of Remote vs. In-Person and Remote Visits that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 200 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06822049, a Phase 2 study of Remote vs. In-Person and Remote Visits, is actively recruiting participants, sponsored by State University of New York at Buffalo.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
2
Study locations

Study Summary

The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.

Interventions

  • DRUG Combination Nicotine Replacement Therapy (patch and lozenge)

Study Locations (2)

New York

  • University at Buffalo - Buffalo

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-03-10
Est. Completion 2027-02-28
Phase Phase 2

What the Registry Record Tells You About NCT06822049

The ClinicalTrials.gov registry entry for NCT06822049 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Remote vs. In-Person appearing as the primary indexed condition, and to 1 intervention - of which Combination Nicotine Replacement Therapy (patch and lozenge) is the first listed.

NCT06822049 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06822049 about?

NCT06822049 is a clinical study titled "Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)". The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessm...

What is the current status of trial NCT06822049?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-03-10. Estimated completion is 2027-02-28.

What conditions does trial NCT06822049 study?

This clinical trial studies the following conditions: Remote vs. In-Person, Remote Visits, In-person Visits.

What interventions are being tested in trial NCT06822049?

The interventions under investigation include: Combination Nicotine Replacement Therapy (patch and lozenge) (DRUG).

Who is sponsoring clinical trial NCT06822049?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06822049 being conducted?

This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.